Variable | N (%) | 5-year Disease-free Survival (%) | Univariate Analysis P | Multivariate Analysis* | |
---|---|---|---|---|---|
P | Hazard Ratio (95% CI) | ||||
Sex | Â | Â | .649 | Â | Â |
Male | 29 (48) | 38 | Â | Â | Â |
Female | 32 (52) | 32 | Â | Â | Â |
BMI (Body Mass Index) | Â | Â | .635 | Â | Â |
 < 25 | 28 (46) | 29 |  |  |  |
 ≥25 | 33 (54) | 38 |  |  |  |
Patient age at resection | Â | Â | .006 | NS | Â |
 ≥ 60 years | 21 (35) | 16 |  |  |  |
 18–59 years | 38 (62) | 47 |  |  |  |
 <  18 years | 2 (3) | 50 |  |  |  |
Tobacco use | Â | Â | .738 | Â | Â |
 Yes | 15 (25) | 40 |  |  |  |
 No | 46 (75) | 28 |  |  |  |
Tumour entity | Â | Â | .311 | Â | Â |
 Leiomyosarcoma | 19 (31) | 31 |  |  |  |
 Liposarcoma, dedifferentiated | 14 (23) | 22 |  |  |  |
 Liposarcoma, well-differentiated | 12 (20) | 33 |  |  |  |
 Undifferentiated sarcoma, NOS | 8 (13) | 25 |  |  |  |
 Liposarcoma, pleomorphic | 3 (5) | 39 |  |  |  |
 Malignant Peripheral Nerve Sheath Tumours | 3 (5) | 29 |  |  |  |
 Other | 3 (5) | 66 |  |  |  |
Histologic grade, n (%) |  |  | .018 | .013 | 2.07 (1.17–3.66) |
 Low grade (G1) | 21 (34) | 63 |  |  |  |
 Intermediate grade (G2) | 11 (18) | 24 |  |  |  |
 High grade (G3) | 29 (48) | 22 |  |  |  |
AJCC 8th Ed., n (%) | Â | Â | .004 | NS | Â |
 Stage IA | 2 (3) | 85 |  |  |  |
 Stage IB | 17 (28) | 71 |  |  |  |
 Stage II | 4 (7) | 50 |  |  |  |
 Stage IIIA | 8 (13) | 36 |  |  |  |
 Stage IIIB | 25 (41) | 28 |  |  |  |
 Stage IV | 5 (8) | 0 |  |  |  |
Chemotherapy n (%) | Â | Â | .150 | Â | Â |
 None | 49 (80) | 34 |  |  |  |
 Neoadjuvant | 2 (3) | 50 |  |  |  |
 Adjuvant | 10 (16) | 31 |  |  |  |
Radiotherapy | Â | Â | .330 | Â | Â |
 None | 44 (72) | 33 |  |  |  |
 Neoadjuvant | 4 (7) | 50 |  |  |  |
 Adjuvant | 13 (21) | 66 |  |  |  |
Surgical resection margin |  |  | .047 | .014 | 3.12 (1.26–7.72) |
 R0 | 33 (54) | 53 |  |  |  |
 R1 | 18 (30) | 10 |  |  |  |
 R2 | 2 (3) | 0 |  |  |  |
 RX / Not stated | 8 (13) | 44 |  |  |  |
Vascular involvement |  |  | .044 | .001 | 5.04 (1.90–13.33) |
 Yes | 17 (28) | 33 |  |  |  |
 No | 44 (72) | 39 |  |  |  |
ASA physical status | Â | Â | .659 | Â | Â |
 I | 12 (20) | 48 |  |  |  |
 II | 32 (52) | 36 |  |  |  |
 III | 14 (23) | 23 |  |  |  |
 IV | 3 (5) | 33 |  |  |  |
Need for intraoperative transfusions, % | Â | Â | .899 | Â | Â |
 No RBCC | 32 (52) | 38 |  |  |  |
 1–2 RBCC | 13 (21) | 41 |  |  |  |
 ≥ 3 RBCC | 16 (26) | 37 |  |  |  |